EMPAGLIFLOZIN AND LINAGLIPTIN

1966 reported adverse events

Drug classes: Dipeptidyl Peptidase 4 Inhibitor [EPC] Sodium-Glucose Cotransporter 2 Inhibitor [EPC]

These side effects are most commonly reported by patients taking EMPAGLIFLOZIN AND LINAGLIPTIN:

# Side effect Count
0 BLOOD GLUCOSE INCREASED 152
1 DIABETIC KETOACIDOSIS 149
2 NAUSEA 106
3 FUNGAL INFECTION 92
4 WEIGHT DECREASED 87
5 DIZZINESS 76
6 VOMITING 71
7 URINARY TRACT INFECTION 66
8 FATIGUE 59
9 DRUG INEFFECTIVE 56
See all common reactions for EMPAGLIFLOZIN AND LINAGLIPTIN

EMPAGLIFLOZIN AND LINAGLIPTIN is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HYPERGLUCAGONAEMIA 1 0.3333
1 CANDIDA URETHRITIS 1 0.3333
2 CAROTID REVASCULARISATION 1 0.1000
3 PENILE ODOUR 1 0.0417
4 CEMENTOPLASTY 1 0.0312
5 BULLOUS ERYSIPELAS 1 0.0303
6 APPENDICEAL MUCOCOELE 1 0.0303
7 PARAMETRITIS 1 0.0294
8 DIABETIC GLAUCOMA 1 0.0278
9 NASAL CAVITY PACKING 1 0.0270
See all enriched reactions for EMPAGLIFLOZIN AND LINAGLIPTIN